// startup autopsy
Adnavance Technologies
Nucleic acid promise dissolved in the financial crisis
external shockSilent Shutdown
Quiet closure with no public announcement · Fatal mistake: Failed to secure partnership or licensing deal before the 2008 financial crisis eliminated follow-on biotech funding entirely.
Key Events Timeline
FOUNDING
Adnavance Technologies founded to develop nucleic acid-based diagnostics and therapeutics.
FUNDING
Raises initial venture funding to build out nucleic acid platform technology.
FUNDING
Secures final funding round of ~$7.6M as financial markets begin deteriorating.
SHUTDOWN
Adnavance shuts down after failing to secure follow-on funding in post-crisis biotech drought.